selected publications

• article

  • American College of Rheumatology Provisional Criteria for Clinically Relevant Improvement in Children and Adolescents With Childhood-Onset Systemic Lupus Erythematosus.  Arthritis Care and Research.  71:579-590. 2019-01-01
  • Tofacitinib, an oral Janus kinase inhibitor, in patients from Mexico with rheumatoid arthritis: Pooled efficacy and safety analyses from Phase 3 and LTE studies [Tofacitinib, un inhibidor oral de la cinasa Janus, en pacientes Mexicanos con Artritis Reumatoide: análisis de eficacia y seguridad de estudios fase 3 y de extensión a largo plazo].  Reumatologia Clinica.  15:43-53. 2019-01-01
  • Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years.  Arthritis %26 rheumatology (Hoboken, N.J.).  67:2759-2770. 2015-01-01
  • Anti-CD43 and anti-galectin-1 autoantibodies in patients with systemic lupus erythematosus.  Scandinavian Journal of Rheumatology.  39:50-57. 2010-01-01
  • Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis.  Arthritis and Rheumatism.  62:1792-1802. 2010-01-01
  • Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial.  The Lancet.  372:383-391. 2008-01-01
• Guidelines for the treatment of ankylosing spndylitis and its effect in Mexican rheumatology [Fundamentos para el tratamiento de la espondilitis anquilosante y su efecto en la reumatología mexicana].  Gaceta Medica de Mexico. 41-49. 2009-01-01
• Guidelines in RA treatment: Concepts on safety and recomendations using anti-TNF-α inhibitors [Recomendaciones para el tratamiento médico de la artritis reumatoide: Actualización sobre la seguridad de los antagonistas del factor de necrosis tumoral alfa].  252-266. 2009-01-01